Document Detail

Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
MedLine Citation:
PMID:  23212559     Owner:  NLM     Status:  Publisher    
AIM: The aim was to compare the efficacy and toxicity of paclitaxel plus platinum (TP) with gemcitabine plus platinum (GP) in untreated advanced non-small-cell lung cancer by a meta-analysis. METHODS: An extensive literature search was performed for relevant randomized controlled trials. Studies were evaluated for eligibility and quality, and then the data were extracted and analyzed using Review Manager 5.1 software. Publication bias was evaluated according to Begg's funnel plot and Egger's test using Stata/SE version 10.1 software. RESULTS: Six randomized controlled trials including 2,793 patients were ultimately identified. The meta-analysis demonstrated that the efficacy was comparable between TP and GP regimens according to the pooled relative risks (RRs) for overall response rate [0.99, 95 % confidence interval (CI) = 0.88-1.13, p = 0.92], disease control rate (0.96, 95 % CI = 0.90-1.03, p = 0.24) and 1-year survival (0.99, 95 % CI = 0.90-1.09, p = 0.87), and the hazard ratios for overall survival (1.06; 95 % CI = 1.00-1.13, p = 0.07) and time-to-progression of disease (1.05, 95 % CI = 0.97-1.14, p = 0.20). Grade 3-4 nausea or vomiting, anemia and thrombocytopenia were less frequent in the TP group (RR = 0.53, 95 % CI = 0.35-0.78, p = 0.002; RR = 0.37, 95 % CI = 0.30-0.45, p < 0.00001; RR = 0.20, 95 % CI = 0.14-0.27, p < 0.00001; respectively). Grade 3-4 sensory neuropathy, fatigue and neutropenia were comparable between the two groups. Sensitivity analyses in studies of paclitaxel compared with gemcitabine combined with the same platinum strengthened the above conclusion. CONCLUSIONS: Our meta-analysis showed that paclitaxel plus platinum had similar efficacy and less toxicity compared with gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer.
Jingwei Jiang; Xiaohua Liang; Xinli Zhou; Ruofan Huang; Zhaohui Chu; Qiong Zhan
Related Documents :
12142089 - Glottic carcinoma--patterns of failure and salvage treatment after curative radiotherap...
23123509 - Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first...
23688269 - Detection of e2a-pbx1 fusion transcripts in human non-small-cell lung cancer.
24853019 - Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesi...
455229 - In situ carcinoma of the vocal cords.
24628269 - Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome.
9531369 - Ependymoma: results, prognostic factors and treatment recommendations.
7987979 - Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients...
21970659 - An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel v...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-6
Journal Detail:
Title:  International journal of clinical oncology / Japan Society of Clinical Oncology     Volume:  -     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Oncology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Zhong Road, Shanghai, 200040, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reactivity of the phosphinito bridged Pt(i) complex [(PHCy(2))Pt(?-PCy(2)){?(2)P,O-?-P(O)Cy(2)}Pt(PH...
Next Document:  Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome...